» Articles » PMID: 35989037

Update on MR Contrast Agents for Liver Imaging: What to Use and When

Overview
Specialty Radiology
Date 2022 Aug 21
PMID 35989037
Authors
Affiliations
Soon will be listed here.
Abstract

Contrast-enhanced liver MR imaging is an important diagnostic tool for many different liver diseases with the sensitivity and specificity in diagnosing liver diseases typically far exceeding other imaging modalities. The safety profile of GBCA is excellent with minimal adverse events. Both extracellular and hepatobiliary contrast agents offer unique advantages and potential limitations. ECA is excellent for obtaining high-quality arterial phase imaging and can be particularly useful for the evaluation of hepatocellular carcinoma (HCC) in cirrhotic patients. In contrast, hepatobiliary agent (HBA) can help distinguish FNH from adenomas, detect liver metastases, and provide biliary imaging due to their uptake within normal hepatocytes and biliary excretion.

Citing Articles

Liver metastases: The role of magnetic resonance imaging.

Maino C, Vernuccio F, Cannella R, Cortese F, Franco P, Gaetani C World J Gastroenterol. 2023; 29(36):5180-5197.

PMID: 37901445 PMC: 10600959. DOI: 10.3748/wjg.v29.i36.5180.


Multisocietal European consensus on the terminology, diagnosis, and management of patients with synchronous colorectal cancer and liver metastases: an E-AHPBA consensus in partnership with ESSO, ESCP, ESGAR, and CIRSE.

Siriwardena A, Serrablo A, Fretland A, Wigmore S, Ramia-Angel J, Malik H Br J Surg. 2023; 110(9):1161-1170.

PMID: 37442562 PMC: 10416695. DOI: 10.1093/bjs/znad124.


Liver involvement in patients with COVID-19 infection: A comprehensive overview of diagnostic imaging features.

Ippolito D, Maino C, Vernuccio F, Cannella R, Inchingolo R, Dezio M World J Gastroenterol. 2023; 29(5):834-850.

PMID: 36816623 PMC: 9932422. DOI: 10.3748/wjg.v29.i5.834.